Meibomian gland dysfunction may be at root of dry eye

Article

Meibomian gland evaluation should be a part of every optometric evaluation, one expert says.

"The role of meibomian gland dysfunction in dry eye is becoming increasing clear, and we believe the vast majority of MGD is non-obvious," he said. "The only way to determine if a meibomian gland is functioning is by expressing it. Expression of the gland should be part of every routine exam, whether the patient has dry eye symptoms or not."

Meibomian gland evaluation is not difficult, according to Dr. Blackie. "You simply need to do a diagnostic expression, which means digitally manipulating the lid margins to express or attempt to express some oil out of the gland orifice," she said. "If no oil is expressed from the orifice, that gland could be considered to be dysfunctional even if the surrounding anatomy of the lid looked totally normal."

"The trouble with our current definition of MGD is that it assumes there will be inflammation," Dr. Korb said. "The new model of non-obvious meibomian gland dysfunction is based on the concept that most of the time, there is no inflammation, therefore you can't see the dysfunction so you must express. It's an idea whose time has come."

There are two basic treatment methods to clear an obstruction in a meibomian gland. Squeezing the gland to express the obstructive material is the most effective, but it's painful for both the patient and practitioner, according to Dr. Korb.

A less aggressive (albeit less effective) therapy involves the use of warm compresses to heat the gland material with the goal of melting or liquefying it, so that it will be expressed naturally during lid blinking or squeezing.

Another therapy option

"You can also try cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan Inc.) because there are some claims that it can improve the quality of meibomian gland secretion," Dr. Blackie said.

"There's also a reasonable amount of data that systemic antibiotics or topical azithromycin ophthalmic solution 1% (AzaSite, Inspire Pharmaceuticals) can be helpful in the case of meibomian gland dysfunction where you have serious inflammation and infection, but antibiotics don't address the need to remove the obstruction," she added.

Along with removal of the obstruction, treatment should include increasing lipid layer thickness and quality with the goal of reducing mechanical trauma and inflammation and any accompanying lid wiper epitheliopathy.

FYI

Donald R. Korb, OD
Phone: 617/423-6370;
E-mail: drkorb@aol.com

Caroline Blackie, OD, PhD
Phone: 617/423-6370
E-mail: cblackie@tearscience.com

Drs. Korb and Blackie receive research funding from Korb Associates, Boston, MA, and TearScience, Morrisville, NC. Dr. Korb is the inventor of SootheXP (Bausch + Lomb).

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
© 2025 MJH Life Sciences

All rights reserved.